Welcome to our dedicated page for MARVEL BIOSCIENCES news (Ticker: MBCOF), a resource for investors and traders seeking the latest updates and insights on MARVEL BIOSCIENCES stock.
Marvel Biosciences Corp. develops novel therapies for autism spectrum disorder and related neurological and neurodevelopmental disorders through its wholly owned subsidiary, Marvel Biotechnology Inc. The company's lead therapeutic candidate, MB-204, is described as a fluorinated derivative of Istradefylline and an adenosine A2A receptor blocker.
Company news commonly covers MB-204 development, pediatric-friendly oral liquid formulation work, intellectual-property protection for purine compounds, scientific and partnering activity in neuroscience, and broader clinical or regulatory disclosures. Updates also reference potential disease areas tied to A2A receptor biology, including autism, depression, Alzheimer's disease, Rett syndrome and Fragile X syndrome, as well as capital-structure matters relevant to the public company.
Marvel Biosciences announced a proposed non-brokered private placement of up to 10,000,000 units at $0.10 per unit, aiming to raise $1,000,000. Each unit includes one common share and one warrant, allowing purchase at $0.15 per share for two years. A triggering event could accelerate the warrant expiry. Finders may receive a fee up to 7% of the proceeds in cash and finder's warrants. The offering targets accredited investors and is subject to a four-month hold period and TSX Venture Exchange approval. Funds will support pre-clinic experiments on MB-204 for Alzheimer's and Autism models, and cover working capital.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.